The Impact of EBV Load on T-Cell Immunity in Pediatric Thoracic Transplant Recipients

Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Transplantation (Impact Factor: 3.83). 08/2009; 88(1):123-8. DOI: 10.1097/TP.0b013e3181aacdd7
Source: PubMed


Immunologic monitoring of pediatric transplant (Tx) recipients, who are at increased risk of Epstein-Barr virus (EBV)-driven posttransplant lymphoproliferative disease, is an important goal in clinical transplantation. Here, we investigated the impact of EBV load on T-cell immunity from pediatric Tx recipients, using clinically applicable tests for improved assessment of T-cell immune competence.
Thirty-five asymptomatic pediatric thoracic Tx patients were categorized into three groups according to their EBV load levels as follows: undetectable viral load (UVL), chronic low viral load (LVL) and chronic high viral load (HVL). Global and EBV-specific T-cell immunity were assessed by ATP release using Cylex Immuknow and T Cell Memory assays.
UVL patients exhibited normal ATP release to Concanavalin A (ConA) and phytohemagglutinin (PHA; 190+/-86 ng/mL, 328+/-163 ng/mL) and detectable EBV-specific (37+/-34 ng/mL) ATP responses. LVL patients displayed significantly stronger responses to ConA (373+/-174 ng/mL), PHA (498+/-196 ng/mL) and EBV (152+/-179 ng/mL), when compared with UVL or to HVL patients (ConA 185+/-114 ng/mL, PHA 318+/-173 ng/mL, and EBV 33+/-42 ng/mL). Moreover, HVL patients displayed significant inverse correlation between CD4+ T-cell ATP levels and EBV loads.
Evaluation of global and EBV-specific T-cell immunity provides a rapid assessment of patients' immune competence. It is still unclear whether selective oversuppressed ATP release by CD4+ T cells reflects HVL patients at risk of posttransplant lymphoproliferative disease. Further longitudinal studies will determine the importance of Immuknow test in identifying asymptomatic HVL patients vulnerable to EBV complications.

Download full-text


Available from: Iulia Popescu, Aug 17, 2014
1 Follower
21 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Data on immune responses of young children using ATP release-based Cylex assay are insufficient. This study measured the immune response of healthy children less than three years of age to mitogens, PHA and Con-A. Blood was obtained from children attending routine health care visits. The Cylex assay was used to measure ATP production by CD4+ and CD3+ cells in response to PHA and Con-A, respectively. Samples from 20 children less than three years (range 10-27 months) were evaluated. The mean ATP production by CD4+ lymphocytes following PHA stimulation was 376 ng/mL (95% CI 17.1-735), which was similar to the response of older children in Hooper et al.'s (Clin Transplant 2005;19:834) study (p-value 0.28). The mean and median ATP production by CD3+ cells following Con-A stimulation were 114 ng/mL and 93.3 ng/mL, respectively (95% CI for median 45.2,148.6). The data suggest that although the immune system of young infants and toddlers is evolving, they are still able to respond to mitogen stimulation similar to older children.
    Pediatric Transplantation 03/2010; 14(5):664-6. DOI:10.1111/j.1399-3046.2010.01321.x · 1.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epstein-Barr virus (EBV) DNA measurement is being incorporated into routine medical practice to help diagnose, monitor, and predict posttransplant lymphoproliferative disorder (PTLD) in immunocompromised graft recipients. PTLD is an aggressive neoplasm that almost always harbors EBV DNA within the neoplastic lymphocytes, and it is often fatal if not recognized and treated promptly. Validated protocols, commercial reagents, and automated instruments facilitate implementation of EBV load assays by real-time PCR. When applied to either whole blood or plasma, EBV DNA levels reflect clinical status with respect to EBV-related neoplasia. While many healthy transplant recipients have low viral loads, high EBV loads are strongly associated with current or impending PTLD. Complementary laboratory assays as well as histopathologic examination of lesional tissue help in interpreting modest elevations in viral load. Circulating EBV levels in serial samples reflect changes in tumor burden and represent an effective, noninvasive tool for monitoring the efficacy of therapy. In high-risk patients, serial testing permits early clinical intervention to prevent progression toward frank PTLD. Restoring T cell immunity against EBV is a major strategy for overcoming PTLD, and novel EBV-directed therapies are being explored to thwart virus-driven neoplasia.
    Clinical microbiology reviews 04/2010; 23(2):350-66. DOI:10.1128/CMR.00006-09 · 17.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cellular assays have been used to assess the pre- and post-transplant immune status of recipients throughout the history of clinical transplantation. Initially, bulk culture assays were used; however, more recent refinements in the techniques allow for assaying multiple functions simultaneously including cell subset functional analysis and the response at the single cell level. The intracellular ATP synthesis assay is being incorporated routinely into the clinical testing strategy. Both donor-specific and non-specific testing strategies are being used to evaluate the immune status of recipients allowing for potential points of intervention aimed at decreasing the adverse impact of clinical complications. This review focuses on the current use of cellular testing in clinical transplantation.
    Tissue Antigens 06/2010; 75(6):658-67. DOI:10.1111/j.1399-0039.2010.01441.x · 2.14 Impact Factor
Show more